Skip to content

Correlation study between SIRI, SII, NLR and the clinical progression of BPH/LUTS and the therapeutic effect of benign prostatic hyperplasia surgery

Correlation study between SIRI, SII, NLR and the clinical progression of BPH/LUTS and the therapeutic effect of benign prostatic hyperplasia surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098461
Enrollment
Unknown
Registered
2025-03-07
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

cross-sectional study group of benign prostatic hyperplasia :none
Benign prostatic hyperplasia surgical group:none

Sponsors

Wuxi No.2 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1.Individuals aged 60 years or older; 2.Diagnosed of BPH based on prostate biopsy; 3.Experiencing one or more LUTS, such as frequent urination, urgency, dysuria, weak urine flow, increased nocturnal urination, etc.; 4.Received standard treatment for the first time at our hospital; 5.Able to cooperate with the completion of relevant laboratory tests, imaging examinations, and psychological health questionnaires.

Exclusion criteria

Exclusion criteria: 1.Severe untreated systemic diseases or other unstable physical condition; 2.Urological malignancies or combined systemic tumors; 3.Serious mental illnesses, severe anxiety or depression disorder and senile dementia; 4.Severe untreated systemic diseases or unstable physical conditions of other diseases; 5.History of previous prostate surgery. 6.Use anti-inflammatory drugs for various reasons in the past 4 weeks.

Design outcomes

Primary

MeasureTime frame
White blood cell count ;Neutrophil count ;Lymphocyte count ;Monocyte count ;Eosinophil count ;Basophil count ;Red blood cell count ;Platelet count ;Platelet volume ;Platelet width ;C-reactive protein ;

Secondary

MeasureTime frame
triglyceride;Total cholesterol;high density lipoprotein;low density lipoprotein;apolipoprotein;lipoprotein;tensin converting enzyme;glomerular filtration rate;retinol conjugated protein;blood glucose;albumin-globulin ratio;

Countries

China

Contacts

Public ContactNinghan Feng

Wuxi No.2 People's Hospital

n.feng@jiangnan.edu.cn+86 138 6189 2528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026